Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Twice a Week in Adult Patients With Advanced Solid Malignancies Including Lymphoma

NCT00471367 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00471367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00471367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Twice a Week in Adult Patients With Advanced Solid Malignancies Including Lymphoma
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Terminated
Start date
April 30, 2007
Completion date
December 31, 2008
Enrollment
44 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, nhl, non-hodgkin lymphoma